Inhibition of angiogenesis is an important new modality for cancer treatment. 2-methoxyestradiol (2ME2) is a novel antitumor and antiangiogenic agent, currently in clinical trials, whose molecular mechanism of action remains unclear. Herein, we report that 2ME2 inhibits tumor growth and angiogenesis at concentrations that efficiently disrupt tumor microtubules (MTs) in vivo. Mechanistically, we found that 2ME2 downregulates hypoxia-inducible factor-1 (HIF) at the posttranscriptional level and inhibits HIF-1-induced transcriptional activation of VEGF expression. Inhibition of HIF-1 occurs downstream of the 2ME2/tubulin interaction, as disruption of interphase MTs is required for HIF-␣ downregulation. These data establish 2ME2 as a small molecule inhibitor of HIF-1 and provide a mechanistic link between the disruption of the MT cytoskeleton and inhibition of angiogenesis.
Introduction
2001; Masson et al., 2001 ) by specific HIF-prolyl hydroxylases in the presence of iron and oxygen (Bruick and McKnight, 2001; Epstein et al., 2001 ). The hydroxylated protein is then recognized Angiogenesis, the development of new blood vessels from preexisting vasculature, is essential during embryonic developby the von Hippel-Lindau tumor suppressor protein (pVHL), which functions as an E3 ubiquitin ligase. The interaction bement. In the adult, angiogenesis occurs under physiological conditions in highly regulated processes such as wound healing tween HIF-1␣ and pVHL is further accelerated by acetylation of lysine residue 532 through an N-acetyltransferase (Jeong et and ovulation. Under pathological conditions, angiogenesis supports the development of many diseases, including cancer, al., 2002) . Under hypoxia, HIF-1␣ is not hydroxylated, which prevents its interaction with pVHL and its subsequent ubiquitinarheumatoid arthritis, psoriasis, macular degeneration, and diabetic retinopathy ). In the case of cancer, angiotion and degradation. Following hypoxic stabilization, HIF-1␣ is translocated to the nucleus where it heterodimerizes with HIF-1␤ genesis is essential for the growth, progression, and metastasis of a tumor and, thus, agents that inhibit angiogenesis are attrac-(ARNT, arylhydrocarbon receptor nuclear translocator) and activates the transcription of more than 40 genes important for tive therapeutic options (Hlatky et al., 2002; Weidner et al., 1991) . Vascular endothelial growth factor (VEGF) is a major adaptation and survival under hypoxia (Brahimi-Horn et al., 2001; ; Semenza, mediator of angiogenesis (Carmeliet et al., 1996; Risau, 1997) ; whose expression is induced under hypoxic conditions (Gold-2002) . HIF-1␣ is overexpressed in more than 70% of human canberg and Schneider, 1994; Minchenko et al., 1994; Shweiki et al., 1992) . Induction of VEGF under hypoxic conditions is a cers and their metastases compared to their adjacent normal tissue, including breast, prostate, brain, lung, and head and multistage process in which the ␣ subunit of hypoxia-inducible factor-1 (HIF-1␣) plays a key role (Forsythe et al., 1996) . HIFneck cancers (Aebersold et al., 2001; Beasley et al., 2002; Birner et al., 2000 Birner et al., , 2001 Blancher et al., 2000; Bos et al., 2001 ; Giatro-1␣ is rapidly degraded by the proteasome under normoxic conditions. This occurs through HIF-1␣ protein hydroxylation on manolaki et al., 2001; Koukourakis et al., 2002; Schindl et al., 2002; Talks et al., 2000; Zhong et al., 1999) . However, the preproline residues 402 and 564 (Ivan et al., 2001; Jaakkola et al., cise role of HIF in tumor development remains highly controver-1B). Treatment with 2ME2 was specific for the regulated ␣ subunit of HIF-1 and HIF-2, but had no effect on the protein levels sial due to the conflicting results of several tumor models. While one study found that genetic disruption of the HIF-1␣ locus of HIF-1␤ or other transcription factors such as c-fos, NF-B ( Figure 1A , lower panel), and c-jun (data not shown). results in the accelerated growth of poorly vascularized HIF-1␣ Ϫ/Ϫ teratocarcinomas (Carmeliet et al., 1998) , other studTo investigate the effects of 2ME2 treatment on HIF-1 transcriptional activity, we measured VEGF protein levels in the ies have shown that the absence of HIF activity in different models impairs tumor growth (Hopfl et al., 2002; conditioned media from 2ME2-treated MDA-MB-231 cells. Consistent with the reduced levels in HIF-1␣ protein by 2ME2, VEGF 1997; Ryan et al., 1998 Ryan et al., , 2000 . Additional evidence in support of the notion that HIF is not necessarily a positive regulator of levels were also significantly decreased in a dose-dependent manner under both normoxic and hypoxic conditions (Figure tumor growth emerged from a recent study where ES cells lacking VHL and constitutively expressing HIF-␣ subunits did 1C). Similar results were obtained following treatment of PC-3 cells with 2ME2 (data not shown). not promote tumor growth (Mack et al., 2003) .
2-Methoxyestradiol (2ME2) is a naturally occurring derivative To examine whether the downregulation of VEGF expression after exposure of cells to 2ME2 was the result of a direct effect on of estradiol and has been shown to be an orally active, welltolerated small molecule that possess antitumor and antiangio-
HIF-1␣, we tested HIF-1 transcriptional activity using a reporter gene assay ( Figure 1D ). PC-3 cells were transiently transfected genic activity (Pribluda et al., 2000) . 2ME2 has low affinity for estrogen receptors ␣ and ␤, and its antiproliferative activity is with a construct containing Luciferase gene under the control of the hypoxia response elements (HRE) from the VEGF promoter independent of the interaction with those receptors (LaVallee et al., 2002) . Several mechanisms have been proposed for 2ME2 ). The results show that 2ME2 treatment also blocked the hypoxia-induced transcriptional activity of activity, including those mediated by its ability to bind to the colchicine binding site of tubulin (Cushman et al., 1995 ; D'Amato HIF-1. To further investigate the effects of 2ME2 treatment on the DNA binding activity of HIF, we performed an electrophoretic et al., 1994) and the inhibition of superoxide dismutase enzymatic activity (Huang et al., 2001 ). However, some of these mobility shift assay (see Supplemental Figure S1 at http://www. cancercell.org/cgi/content/full/3/4/363/DC1). Consistent with findings have been disputed (Attalla et al., 1996; Kachadourian et al., 2001) , and the process by which 2ME2 inhibits tumor the gene reporter assay ( Figure 1D ), HIF DNA binding activity was also attenuated in the 2ME2-treated samples. Collectively, growth and angiogenesis is still not well understood.
Here we report on a novel mechanism mediating the antituthese results suggest that 2ME2 inhibits the hypoxia-induced DNA binding and transcriptional activity of HIF. mor and antiangiogenic activity of 2ME2. Our findings demonstrate that 2ME2 destabilizes microtubules at doses that are
To determine whether downregulation of HIF-1␣ by 2ME2 occurred at the transcriptional level, we treated MDA-MB-231 efficacious in vivo. At concentrations that have antiproliferative activity in tumor cells in vitro, 2ME2 blocks HIF-1␣ nuclear cells with 2ME2 and performed Northern blot analysis ( Figure  2A ). HIF-1␣ mRNA levels were not significantly changed by accumulation and HIF-1 activity by an oxygen-and proteasomeindependent pathway. We further show that this mechanism is 2ME2 even at very high concentrations (100 M). Similar results were obtained when we analyzed the expression levels of shared by other MT-targeting drugs, such as taxol, and we provide evidence for a link between the microtubule cytoskele-HIF-1␣ mRNA with quantitative RT-PCR (data not shown). As expected, hypoxic exposure of the untreated cells resulted in ton and HIF regulation. a robust induction (Ͼ20-fold) induction in VEGF mRNA ( Figure  2A ). 2ME2 treatment significantly decreased VEGF mRNA under Results normoxia (16-fold decrease) and hypoxia (41-fold decrease). It is of note that 2ME2 inhibited VEGF mRNA ( Figure 2A ) and 2ME2 reduces expression of HIF-1␣ and VEGF in prostate and breast cancer cells secretion ( Figure 1C ) under normoxic conditions as well. This finding is consistent with the inhibition of HIF-1␣ protein levels 2ME2 is an effective inhibitor of tumor growth and angiogenesis in numerous in vivo models (Fotsis et al., 1994; Klauber et al., by 2ME2 under normoxia. This could be explained by the notion that regulation of VEGF expression in cancer cells with substan-1997; Pribluda et al., 2000) . Although various molecular targets have been proposed for this compound, its mechanism of action tial normoxic levels of HIF-1␣ protein is mediated in part by HIF. In addition, 2ME2 treatment inhibited two other HIF-1 target remains unclear. HIF-1 is a proangiogenic transcription factor stabilized and activated under hypoxia. HIF-1 activates angiogenes, namely Glut-1 glucose transporter and endothelin-1 (ET-1). This result further confirms that 2ME2 inhibits HIF-1-genesis via transcriptional activation of VEGF, among other genes, and consequently is an important tumor survival factor. mediated transcriptional activation of target genes, including VEGF, without affecting the transcription of HIF-1␣ itself. In this study, we sought to investigate whether regulation of the HIF-1 pathway could contribute to the antiangiogenic effects To obtain a better understanding of the processes involved in HIF-1␣ inhibition by 2ME2, we studied the effect of 2ME2 of 2ME2. We first examined the effects of 2ME2 treatment on HIF-1␣ protein in the human prostate cancer cells PC-3 (Figure on HIF-1␣ posttransciptional regulation. We examined 2ME2 effects on HIF-1␣ protein stability by using the protein transla-1A) and in the human breast cancer cells MDA-MB-231 ( Figure  1B ). As shown in Figure 1 , 2ME2 treatment of PC-3 and MDAtion inhibitor cycloheximide (CHX) ( Figure 2B ) and a pulse-chase assay ( Figure 2C ). In the presence of CHX, new protein synthesis MB-231 cells reduced the levels of nuclear and total HIF-1␣ protein as detected in nuclear (NE) and whole-cell extract (WCE) is inhibited, thus HIF-1␣ levels would predominantly reflect the degradation process of HIF-1␣ protein. Untreated or 2ME2-preparations. This inhibition was dose dependent and seen under both normoxic and hypoxic conditions. HIF-2␣, which has treated cells were exposed to CHX for various times and HIF-1␣ protein levels were analyzed by Western blotting. Within 10 been reported to be regulated similarly to HIF-1␣ (Semenza, 2000; Wenger, 2000) , is also downregulated by 2ME2 ( Figure  min of exposure to CHX ( Figure 2B ), HIF-1␣ protein levels from both untreated and treated cells were decreased to about 60%. tion and degradation through the proteasome, we performed the experiments shown in Figure 2E and Figure S2 (see SuppleAlthough the intensity of the HIF-1␣ signal is different at the zero time point, the degradation rates of HIF-1␣ protein are mental Data on Cancer Cell website). PC-3 cells were treated with 2ME2 in the presence or absence of the proteasome inhibisimilar in the absence or the presence of 2ME2 ( Figure 2B ). This was further confirmed when cells were labeled with 35 Stor MG-132 ( Figure 2E ). In untreated cells, MG-132 resulted as expected in enhanced HIF-1␣ protein levels and multiple higher methionine and pulse-chased in the presence or absence of 2ME2, and HIF-1␣ protein levels were then analyzed. The halfmolecular weight species, which most likely correspond to polyubiquinated HIF-1␣ protein conjugates ( Figure 2E , arrows). In life of HIF-1␣ from 2ME2-treated cells was approximately 1.5 hr compared to 2.3 hr in the untreated cells. Again, as shown 2ME2-treated cells, however, MG-132 did not restore the inhibitory effect of 2ME2 on HIF-1␣ protein levels in hypoxia or norin the graph by the slope of the two curves, the rates of HIF-1␣ protein loss are similar under both conditions. Thus, 2ME2 moxia, suggesting that 2ME2 does not increase HIF-1␣ proteasomal-mediated degradation. To further examine whether 2ME2 does not seem to directly affect HIF-1␣ protein stability since the rate of decrease of HIF-1␣ protein from both assays (Figures effects could be attributed to enhanced HIF-1␣ ubiquitinylation, we transiently transfected cells with FLAG-tagged HIF-1␣ and 2B and 2C) is similar in treated and untreated cells.
Following this observation, we next examined the effect of examined the accumulation of the ubiquitinated forms of HIF-1␣ in the presence or absence of 2ME2 (see Supplemental Figure  2ME2 on HIF-1␣ protein translation. PC-3 cells were labeled with 35 S-methionine in the presence or absence of 2ME2 for the S2 on Cancer Cell website). In the presence of 2ME2, there was no change in the amount of ubiquinated HIF-1␣ compared to indicated times (min) ( Figure 2D ). After 15 min of labeling, HIF-1␣ protein synthesis was at least 10-fold higher in the untreated control, indicating that 2ME2 affected HIF-1␣ prior to the ubiquinitation step. cells compared with the 2ME2-treated ones ( Figure 2D ). Together with the results of the protein stability experiments, this Although, we cannot exclude an indirect effect of 2ME2 on HIF-1␣ protein degradation through proteasome-independent result suggests that 2ME2 treatment inhibits HIF-1␣ protein synthesis rather than enhancing its degradation. To further expathways, our results together with reports on other small molecules (e.g., geldanamycin) known to accelerate HIF-1␣ protein clude the possibility that 2ME2 accelerates HIF-1␣ ubiquitina- Figure 2 . 2ME2 has no effect on HIF-1␣ mRNA levels or rate of protein degradation A: Total RNA was prepared from 2ME2-treated MDA-MB-231 cells under normoxic and hypoxic conditions, and Northern blotting was performed with 32 Plabeled HIF-1␣ and VEGF 165 , Glut1, ET-1 probes. ␤-actin is shown as a loading control. Quantification of the expression levels of VEGF by densitometry was performed using ␤-actin. B: Upper panel: PC-3 cells were treated overnight with either vehicle (0.01% DMSO) or 10 M 2ME2 and cycloheximide (CHX) was added at a final concentration of 10 g/ml for the indicated time. Equal amounts of protein from each sample were resolved by SDS-PAGE, and Western blotting was performed with antibodies against HIF-1␣ or actin. Lower panel shows quantification of the HIF-1␣ signal by densitometry following normalization to actin levels. HIF-1␣ levels from untreated cells or 2ME2-treated cells are arbitrarily given the value of 100%. C: PC-3 cells were labeled with 35 S-methionine and pulse-chased in complete medium containing either 0.1% DMSO or 100 M 2ME2 for the indicated time (h). Upper panel: equal amounts of protein from each cell lysate were subjected to immunoprecipitation with anti-HIF-1␣ antibody, resolved by SDS-PAGE, and subjected to autoradiography. Lower panel: quantification of the autoradiographic HIF-1␣ signal by densitometry. D: PC-3 cells were pretreated overnight with either vehicle (0.025% DMSO) or 25 M 2ME2. The cells were then labeled with 35 S-methionine in the presence or absence of 25 M 2ME2 for the indicated time (min). Upper panel: equal amounts of protein from each cell lysate were subjected to immunoprecipitation with anti-HIF-1␣ antibody, resolved by SDS-PAGE, and subjected to autoradiography. Lower panel: quantification of the autoradiographic HIF-1␣ signal by densitometry. E: PC-3 cells were treated with 100 M 2ME2 in the presence and absence of 10 M MG-132 for 4 hr. Equal amounts of protein from each cell lysate were resolved by SDS-PAGE, transferred, and immunoblotted with antibodies against HIF-1␣ and TOPO-I. Arrows point to ubiquinated HIF-1␣ protein species.
ubiquitinylation and proteasomal degradation (Isaacs et al., Therefore, we sought to investigate whether there is any correlation between the effects of 2ME2 on microtubules and 2002; Mabjeesh et al., 2002) suggest that 2ME2 reduces HIF-1␣ protein levels through a translational-dependent pathway rather its effects on HIF-1. We assessed this by laser scanning confocal microscopy (LSCM) in PC-3 cells treated with 2ME2 ( Figure 3A ). than affecting HIF-1␣ protein stability.
The cells were double-labeled with antibodies against ␣-tubulin (red) and HIF-1␣ (green) ( Figure 3A ). We observed a dose-2ME2 depolymerizes microtubules and inhibits nuclear accumulation of HIF-1␣ dependent depolymerization of microtubules in the 2ME2-treated cells (solid arrows) compared to the fine and intricate 2ME2 has been shown to bind to the colchicine binding site of tubulin (D'Amato et al., 1994) and to depolymerize microtubules microtubule network observed in untreated control cells. No significant changes in the microtubule network were observed in endothelial (Fotsis et al., 1994) as well as in tumor cells (AizuYokota et al., 1995) , resulting in mitotic arrest and cell death.
in untreated cells after hypoxia. On the other hand, while HIF-1␣ was barely detectable under normoxic conditions, it predomiHowever, there are also reports demonstrating that the antiproliferative activity of 2ME2 may occur independently of the destanantly accumulated in the nucleus after exposure to hypoxia ( Figure 3A , green staining). Nuclear localization of HIF-1␣ was bilization of microtubules (Attalla et al., 1996) or by actually stabilizing microtubules (Purohit et al., 1999) .
confirmed by double-labeling with DAPI (data not shown). 2ME2 treatment significantly reduced the hypoxia-induced nuclear acto 2ME2, both taxol and vincristine blocked the hypoxia-induced nuclear accumulation of HIF-1␣ ( Figure 3B ) while they had no cumulation of HIF-1␣. To examine whether these effects were specific for the regulated subunit of HIF-1, HIF-1␣, we also effect on HIF-1␤ ( Figure 3B and vincristine data not shown). To confirm the data obtained by immunofluorescence and LSCM, tested the effects of 2ME2 on HIF-1␤. As seen at the bottom panel of Figure 3A , 2ME2 treatment had no effect on either we analyzed HIF-1␣ protein levels and HIF-1 transcriptional activity in cells treated with taxol and vincristine, utilizing 2ME2 HIF-1␤ (green) levels or on HIF-1␤ subcellular localization. In untreated cells, HIF-1␤ was localized predominantly in the nuas a positive control. Consistent with what was observed with 2ME2 and with their effects on microtubules ( Figure 3B ), taxol cleus, and it was not further accumulated after hypoxia (data not shown).
and vincristine also reduced HIF-1␣ protein levels in a dosedependent manner ( Figure 3C ) and inhibited HIF-1 transcripTo determine if the inhibition of HIF-1␣ was a general property of MT-targeting agents or whether it was specific to 2ME2, tional activity ( Figure 3C ). Since MT-targeting drugs are known to cause mitotic arrest, we tested other MT-disrupting agents that either destabilize (vincristine) or stabilize (taxol) MTs ( Figure 3B ). Treatment of we wanted to exclude the possibility that the effects of 2ME2, taxol, and vincristine on HIF-1␣ were nonspecific and reflected PC-3 cells with taxol stabilized MTs, resulting in distinct microtubules bundles (dashed arrows), while vincristine completely derather a "side effect" of mitotic arrest. Thus, we treated MDA-MB231 cells with monastrol, a compound known to induce polymerized microtubules (solid arrows) ( Figure 3B ). Similarly mitotic arrest by inhibiting the mitotic kinesin Eg5 but to have no effect on the organization or function of the microtubule cytoskeleton (Mayer et al., 1999) . As clearly shown in Figure  3D , monastrol has no effect on HIF-1␣ protein levels (upper panel) even at concentrations that induce a profound mitotic arrest (lower panel). Consistent with previously published reports on monastrol (Gagescu, 2000) and unlike MT-targeting drugs, we also see no effect on interphase microtubules even at concentrations at which monoastral spindles are observed ( Figure 3D, lower panel) . Collectively, these results suggest that the strong link between disruption of the microtubule cytoskeleton and inhibition of HIF-1␣ function is independent of mitotic arrest.
Disruption of the MT cytoskeleton is required for HIF-1␣ inhibition
The data with these three different classes of MT-targeting drugs indicate that there is good correlation between the disruption of the MT cytoskeleton and the inhibition of HIF-1␣. However, the question remains of whether the effects of the MT-targeting drugs on HIF-1␣ are independent from their effects on the MT cytoskeleton. We addressed this question through a genetic approach employing the 1A9 human ovarian carcinoma cells and its taxol-resistant clone, 1A9/PTX10 (Giannakakou et al., 1997) . The 1A9/PTX10 cells are 30-fold resistant to taxol due to an acquired ␤-tubulin mutation at the taxol binding site, while they retain sensitivity to all MT-depolymerizing agents (Giannakakou et al., 1997) including 2ME2 (data not shown). To assess whether drug-induced effects on microtubules are necessary for inhibition of HIF-1␣, we treated the parental 1A9 and the taxol-resistant 1A9/PTX10 cells with taxol and 2ME2 and processed them for LSCM and Western blot analysis ( Figure 4 ). As expected, taxol had no effect on the microtubule network in Figure 4A ). In addition, taxol inhibited HIF-1␣ protein levels treatments overnight followed by hypoxia for an additional 6 hr, and processed for confocal microscopy (A) and Western blotting (B).
in the parental 1A9 cells only, while it had almost no effect on 
2ME2 inhibits angiogenesis at concentrations that disrupt microtubules in vivo
The concentrations of 2ME2 required to observe the effects on treatment, and at 150 mg/kg, there is a significant reduction in microtubules in vitro are much higher than those achievable in tumor volume when compared to the vehicle-treated control vivo. We employed a mouse orthotopic breast tumor model to animals ( Figure 5A ). In addition, time-dependent tumor growth determine whether 2ME2 disrupts microtubules at the same inhibition was also observed in two different animal models of doses at which it exhibits antitumor activity in vivo, and to see human breast cancer cells (see Supplemental Figure S3 on if this also results in a decrease in the tumor microvascular Cancer Cell website). To study the effects of 2ME2 on tumor density. Animals were treated with 2ME2 or cyclophosphamide vascularization, we performed immunohistochemical staining as a non-MT-targeting chemotherapy drug. At the end of treatfor CD31 in untreated and 2ME2-treated animals, and represenment, tumors were excised and processed to assess several tative images are shown in Figure 5B . A clear reduction of CD31 different parameters such as tumor volume, vascularization, and staining is seen in the treated animals compared to controls integrity of the MT cytoskeleton. As seen in Figure 5A , a dosedependent reduction of tumor volume was observed with 2ME2
( Figure 5B, upper panel) . Statistical analysis of microvessel den- MVD in animals treated with 2ME2 compared to controls ( Figure  5B , lower panel). Then we sought to investigate whether the in vivo effects of 2ME2 on MVD correlated with its antitubulin effects, as we kg 2ME2 (animal #19 and #21a, b) possess either completely have seen in our experiments with cultured cells. The in vivo depolymerized MTs (dashed arrows) or multiple mitotic asters effect of 2ME2 on MTs was evaluated by two different assays.
(dotted arrows), which indicate aberrant mitotic arrest. The latter First, we developed a highly sensitive method to allow qualitative is more evident in the lower magnification field shown for animal assessment of the MT cytoskeleton integrity in vivo, using LSCM #21 (21b), where almost every cell displayed has aberrant mitotic of tumor sections stained with an antibody against tubulin as spindles. The tumor cells from animals treated with 30 mg/ described in Experimental Procedures. As shown in Figure 6A , kg 2ME2 (animal #29) also have depolymerized MTs (dashed the tumor cells from vehicle or cyclophosphamide-treated mice arrows) and multiple aberrant mitotic asters (dotted arrows). This paper reports a qualitative assessment of microtubules in (animals #17 and #11, respectively) possess a fine, intricate, and well-organized microtubule network (solid arrows). In convivo. A section of each tumor excised was processed for Western blot for tubulin analysis in order to assess quantitatively the trast, the tumor cells from the animals treated with 150 mg/ relative levels of polymerized and soluble tubulin following 2ME2 2ME2-treated animals were double-labeled with antibodies against ␣-tubulin (red staining) and CD31 (green staining). Caretreatment ( Figure 6B ). In this experiment, we adapted this technique previously developed to assess the effects of MT-tarful examination of the integrity of MTs in CD31-positive endothelial cells revealed MT disruption in the treated animals compared geting drugs on cultured cells (Giannakakou et al., 1997) . From each tumor, the lanes labeled "P" contain the polymerized form to the undisturbed MT network in control animals ( Figure 7B , insets). of tubulin (MTs) and those labeled "S" the soluble form (␣/␤ tubulin dimers). Treatment with 2ME2 depolymerized MTs in a dose-dependent manner. This is evidenced by the decrease Discussion from 70% of polymerized tubulin in the vehicle-treated animal to 3%-9% observed in the animals treated with 2ME2. Thus, Angiogenesis is one of the important biological processes rewe have demonstrated by two independent assays that 2ME2 quired to support tumor growth beyond a certain threshold depolymerizes MTs in vivo (Figure 6 ) at concentrations that size. Therefore, the development of angiogenesis inhibitors has inhibit growth and vascularization of tumors ( Figure 5) .
recently become an attractive new strategy to combat cancer. Careful examination of the in vivo MT staining after 2ME2
In this study, we have identified a novel molecular mechanism treatment suggested that 2ME2 may also have an effect on by which 2ME2, an antitumor agent and angiogenesis inhibitor endothelial cell tubulin, as depicted by the aberrant mitoses currently in phase I/II trials, exerts its activity. Our results show seen in cells that line the vessel in animal #21b ( Figure 6A , thick that 2ME2 depolymerizes MTs and downregulates HIF-1␣ proarrowheads). This observation prompted us to investigate the tein levels and HIF transcriptional activity in an oxygen-and effects of 2ME2 on endothelial cells in vitro and in vivo. As proteasome-independent manner (Figures 1 and 2) . Most imporshown in Figure 7A and similarly to cancer cells (Figures 1-4) , tantly, we demonstrate that at concentrations that inhibit tumor growth and vascularization in vivo, 2ME2 effectively depolymer-2ME2 treatment resulted in a dose-dependent inhibition of HIF-2␣ protein in human umbilical vein endothelial cells (HUVEC) izes tumor MTs. In vitro, 2ME2 has been shown to compete with colchicine (upper panel), which correlated with extensive microtubule depolymerization (lower panel). Decreased DNA binding activity of for tubulin binding and to disrupt interphase MTs leading to mitotic arrest and cell death in cultured cancer cells (Cushman HIF measured by EMSA was observed in 2ME2-treated HUVEC cells compared to control untreated cells (data not shown).
et al. , 1997; D'Amato et al., 1994; Seegers et al., 1997) . In addition, when we treated HUVEC with 2ME2, we observed a We next examined the effects of 2ME2 on endothelial cell tubulin in vivo ( Figure 7B ). Tumor sections from untreated or dose-dependent MT depolymerization at concentrations similar to those used in tumor cells ( Figure 7A ). The antiangiogenic HIF (Figure 4 ). However we have not yet determined what the properties of this compound, however, had not been correlated signaling events are that link MT disruption to HIF-1␣ inhibition. previously with its effects on MTs. Other MT-targeting comInterestingly, a recent study has shown that VHL is a tubulinpounds have also been shown to possess varying degrees of associated protein that helps stabilize interphase microtubules, antiangiogenic activity, including the colchicine site agents potentially identifying a new role for pVHL function in VHL discombretastatins (Dark et al., 1997; Grosios et al., 1999; Tozer ease (Hergovich et al., 2003) . However, how the pVHL stabilizing et al., 2001) and ZD6126 (Blakey et al., 2002) and the taxane effects on MTs may be linked to the VHL-HIF functional regulasite agents, such as taxol, (Belotti et al., 1996; Klauber et al., tion is currently unclear (Ratcliffe, 2003) . Future studies are 1997) docetaxel (Sweeney et al., 2001) , and IDN 5390 (Tarabowarranted to increase our understanding of the molecular mechletti et al., 2002). The above studies led to the hypothesis that anisms that regulate these pathways. the antivascular effects of MT-targeting agents derive from their Taken together, our results show that disruption of inability to selectively inhibit the growth of endothelial cells in terphase MTs results in repression of HIF-1␣, likely at the level tumor vessels, producing vascular shutdown and massive tumor of translation, which in turn leads to inhibition of HIF-1 transcripnecrosis. Our data show that 2ME2 affects in vivo tubulin in tional activity, including downregulation of VEGF expression. both the tumor and endothelial cell compartments (Figures 6 and We have further determined that inhibition of HIF-1␣ by 2ME2 7), which suggests that 2ME2 may interfere with the crosstalk or other MT-targeting compounds occurs downstream of drugbetween cancer and endothelial cells further contributing to the tubulin interaction. This finding provides mechanistic insight into antitumor and antiangiogenic activity of 2ME2.
the antiangiogenic mechanism of action reported for several Decreased VEGF protein levels after 2ME2 treatment have MT-targeting compounds and supports the hypothesis that tubeen reported previously (Banerjeei et al., 2000; Chauhan et al., bulin-targeting drugs inhibit both tumor cell growth and tumor 2002); however, the molecular mechanism responsible for this vascularization following disruption of the MT cytoskeleton. The decrease had not been identified. Our data show that 2ME2 further characterization of the molecular signals linking the disinterferes with the downstream activation of HIF-1 target genes, ruption of the MT cytoskeleton with the downregulation of HIFonly one of which is VEGF, in response to hypoxia (Figure 2) . mediated angiogenesis are likely to identify novel targets for Thus, our current hypothesis is that the antitumor/antiangiothe development of new anticancer therapies. genic activity of 2ME2 likely results from both the inhibition of We believe that pharmacologic inhibition of HIF-1␣ and parthe normal function of tumor MTs and the inhibition of the HIFticularly HIF-regulated genes that are important for cancer cell transcriptome. This hypothesis is supported by data in the literasurvival may be more advantageous than HIF-gene inactivation ture showing that inhibition of VEGF in vivo by the recombinant therapeutic approaches. Conflicting results have emerged from humanized antibody directed against VEGF (rhuMAb-VEGF) led HIF knockout models that showed both accelerated and reto only a 25% inhibition of angiogenesis, whereas 2ME2 inhibtarded tumor growth (Carmeliet et al., 1998; Hopfl et al., 2002 ; ited angiogenesis by 63% (Sweeney et al., 2001 ). This result is Maxwell et al., 1997; Ryan et al., 1998; Ryan et al., 2000) , sugin agreement with our in vivo data where a 64% inhibition of gesting that genetic inactivation of HIF may not be sufficient to angiogenesis was obtained after treatment with 150 mg/kg inhibit tumor growth and angiogenesis due to compensatory 2ME2 (Figure 6 ), and it further suggests that the 2ME2 antiangiosurvival mechanisms acquired by the cancer cells. genic activity might not be solely attributed to inhibition of VEGF.
2ME2 is currently in phase I/II clinical trials in breast, metaAlthough we attempted to show that 2ME2 inhibited HIF-1 in static breast, and prostate cancer. The preliminary results from vivo, we were unable to do so because of the technical challenge these trials show promising responses without any serious drugin staining HIF-1␣ in sections form xenograft tumors, unlike our related adverse effects even when 2ME2 is administered at earlier success in staining patients' specimens for HIF-1␣ from doses of 1,000-1,200 mg/day (Lakhani et al., 2003) . Herein, we a wide variety of different cancers (Zhong et al., 1999) . While show that 2ME2 is a lead compound that has a dual effect on we have not been able to confirm all of our in vitro observations MTs, a validated anticancer drug target, and HIF, which we in vivo, our data support the hypothesis that 2ME2 affects MTs believe is an important survival factor in cancer. and its downstream effects on HIF pathway lead to inhibition of tumor vascularization in vivo. We believe further studies using In our experiments, we have demonstrated that taxol and compound was diluted in incubation media immediately prior to each experivincristine also inhibited HIF-1␣ levels and HIF-1 transcriptional ment. Thawed stock solutions were used once and discarded. Vincristine activity (Figure 3 ). Despite the "opposite" effects of taxol and was from Eli-Lilly (Indianapolis, Indiana), Paclitaxel and Cyclophosphamide vincristine on MT structure (stabilization versus destabilization), were from Sigma (St. Louis, Missouri). it is not surprising that both drugs had similar effects on HIF was purchased from Alexis Biochemicals (San Diego, California). Monastrol since they both disrupt the organization and equally affect the (Mayer et al., 1999) , was not able to downregulate HIF-1 levels rado), human actin antibody from Santa Cruz Biotechnology, Inc. (Santa ( Figure 3D ). We have also demonstrated that the alterations in Cruz, California), and polyclonal human antibody to human topoisomerase the MT cytoskeleton resulting from the interaction of the MT-I (TOPO-I) (TopoGEN, Columbus, Ohio) . Rabbit polyclonal antibodies to c-Jun, c-Fos, NF-B p50, and NF-B p65 were from Geneka Biotechnology, Inc targeting drugs with tubulin are required for the inhibition of (Montré al, Qué bec, Canada) . Secondary antibodies were horseradish peroxivarious times. Subsequently, the cells were washed twice with ice-cold PBS, lysed, and subjected for immunoprecipitation using anti-HIF-1␣ antibody as dase-conjugated (Amersham Pharmacia Biotech, Piscataway, New Jersey), Alexa Fluor 488 goat anti-mouse (Molecular Probes, Eugene, Oregon), Alexa previously described (Mabjeesh et al., 2002) . Fluor 568 goat anti-rat (Molecular Probes, Eugene, Oregon), Rhodamine Red-X mouse anti-rat (Jackson ImmunoResearch, West Grove, Baltimore).
Tumor models and immunohistochemistry Female 8-to 10-week-old BALB/c nu/nu mice (Jackson Laboratories, Bar Harbor, Maine) were injected in the mammary fat pad with 2 ϫ 10 6 MDACell lines Human breast cancer MDA-MB-231 cells were maintained in DMEM and MB-231 cells. Daily oral administration of 2ME2 was initiated when the tumors became palpable (4-5 mm diameter) on day 20 after implantation. human prostate cancer PC-3 cells; 1A9 human ovarian carcinoma cells and its paclitaxel-resistant subline 1A9/PTX10 were cultured in RPMI 1640;
A suspension of 2ME2 was prepared by homogenization in an aqueous solution of 0.5% methylcellulose (Sigma) using a Kinematica polytron (Brink-HUVEC were cultured in M199 media. All media were supplemented with 10% FBS and antibiotics. Cells were cultured at 37ЊC in a humidified atmomann, Westbury, New York). At the end of the dosing regimen on day 53 (treatment duration was 33 days), animals were sacrificed and tumor volumes sphere and 5% CO 2 in air. For hypoxic exposure, cells were placed in a sealed modular incubator chamber (Billups-Rothenberg, Del Mar, California) were calculated as width 2 ϫ length ϫ 0.52. Upon termination of the dosing regimen, animals were euthanized with 20 mg/100 g BW of phenobarbital flushed with 1% O 2 , 5% CO 2 , and 94% N 2 .
(Sigma), and tumors were excised as quickly as possible and cut into 1 mm 2 pieces. One piece of tumor was dounced and placed into 200 l of 2ME2 treatment of cells microtubule-stabilizing buffer and processed for the tubulin polymerization Cells were seeded in culture dishes and grown until 70% confluence. The assay (for details, see below). The rest of tumor pieces were fixed with 3.7% medium was then replaced with a new medium containing either vehicle (0.1% DMSO) or 2ME2 at the concentrations indicated in the figures for formaldehyde, 0.05% glutaraldehyde, and 0.5% Triton X-100 in PHEMO overnight at 37ЊC. The following day, cells were exposed to hypoxia or left buffer for 30 min at room temperature. Then they were transferred into 4% under normoxia for 6 hr. The cells were then washed twice with ice-cold formaldehyde in 0.1 M sodium cacodylate buffer (Sigma) (pH 7.3) for an PBS, harvested, and nuclear extract (NE) was prepared as described (Jiang additional 4 hr. Tumor pieces were stored at 4ЊC in the same buffer until et al., 1996), or alternately, a whole-cell extract (WCE) was prepared by they were immunostained for ␣-tubulin, as described above, and CD-31. lysing the cells with 100 mM potassium phosphate (pH 7.8) and 0.2% Triton X-100 supplemented with protease and phosphatase inhibitors.
Immunohistochemical determination of CD 31/PECAM-1 For immunohistochemistry, tumors were fixed in 10% buffered formalin Immunoblot analysis (Sigma). Paraffin-embedded tissue was sectioned at 5 m and mounted on Proteins (30-60 g/lane) from WCEs or NEs were resolved by 7.5% SDSSuperfrost slides (Fisher Scientific, Co., Houston, Texas). Sections were PAGE, electrotransferred to nitrocellulose membrane, and incubated with deparaffinized in xylene, subsequently immersed in graded alcohol (100%, the indicated primary antibodies, followed by horseradish peroxidase-conju-95% ethanol), rehydrated in ddH 2 O and Tris buffer. Sections were then gated secondary antiserum. Immunoreactivity was visualized by enhanced treated with Protinase K (Roche Indianapolis, Indiana), washed in Tris-buffer, chemiluminescence reagent (Amersham Biosciences, Piscataway, New Jerblocked for endogenous peroxidase activity by use of 3% hydrogen peroxide sey). For sequential blotting with additional antibodies, the membranes were in methanol for 20 min. After blocking sections with TNB block for 45 min stripped using a restore Western blot stripping buffer (Pierce, Rockford, (NEN Life Science Products, Inc. Boston Massachusetts), sections were Illinois) and reprobed with the indicated antibodies.
incubated with anti-CD31 rat anti-mouse antibody (1:250 dilution) at 4ЊC overnight (PharMingen, San Diego, California). Slides were then washed TNT ELISA for VEGF wash buffer (NEN), incubated with species-specific biotinylated secondary VEGF concentration in media from treated cells was determined using ELISA antibody for 30 min (1:200 dilution, Vector Laboratories, Burlingame, Califorkit for VEGF protein (R & D Systems, Inc., Minneapolis, Minnesota) according nia). After secondary incubation slides were washed in TNT buffer, sections to the manufacturers' instructions. The results were expressed as concentrawere amplified with tyramide-horderdase peroxidase (NEN) and visualized tion of VEGF (pg/ml) per the total protein amount from each well.
by incubating the slides with 3, 3Ј-diaminobenzidine (Vector). The slides were counterstained with Gills Hemotoxylin III (Sigma), rinsed, and immersed Transient transfections and reporter gene assay briefly in 1% ammonia solution for nuclei binding. Finally, slides were hy-PC-3 cells were transfected with 1 g/well of a reporter plasmid (pBI-GL V6L) drated and mounted with cytoseal (VWR International, West Chester, Penncontaining HREs from the VEGF gene as previously described (Mabjeesh et sylvania) and covered with Fisherfinest glass cover slips (Fisher). For negative al., 2002; . controls, the exact procedure was done with either the omission of the primary antibody or the secondary. Isolation and analysis of RNA Total RNA was isolated using TRIzol Reagent (Life Technologies, Inc), and Quantification of MVD Northen blotting was performed with probes specific for human HIF-1␣, For quantification of CD31, tumor sections that stained positive for CD31 VEGF 165, endothelin 1 (ET-1), Glut-1 glucose transporter, and ␤-actin (Amvessels were used in the analysis. Microvasular density (MVD) was measured bion, Inc., Austin, Texas) as described (Wang et al., 1995) .
by using Bioquant Image Analysis System (PAI, Frederick, Maryland). To quantify the vessels, ten areas at 168 m 2 per field at ϫ200 were captured for each tumor using Olympus BX 40 microscope. HIF-1␣ protein translation assay PC-3 cells were plated into 6-well plates and grown to 70% confluence. Cells were pretreated overnight with 25 M 2ME2 or DMSO (0.025% vol/ Immunofluorescence and confocal microscopy vol). Then medium was changed to methionine-and cysteine-free as well A. Cell lines as serum-free RPMI 1640 medium for 2 hr. After 2 hr, cells were labeled Exponentially growing cells were plated on 12 mm glass coverslips (Fisher by incubation with methionine-and cysteine-free medium containing 35 SScientific, Pittsburgh, Pennsylvania) into 24-well plates and cells were almethionine (ICN Biomedicals, Inc., California) at a final concentration of 100 lowed to attach overnight. The following day, cells were treated with the Ci/well at 37ЊC for the indicated time in the figure. Subsequently, the cells indicated drugs for 16 hr and subjected to hypoxia for an additional 6 hr. were washed twice with ice-cold PBS, lysed, and subjected for immunopreCells were fixed with PHEMO buffer (PIPES 0.068M, HEPES 0.025 M, EGTA cipitation using anti-HIF-1␣ antibody and protein G-agarose beads (Pierce, 0.015 M, MgCl 2 0.003 M, 10% DMSO, pH 6.8) containing 3.7% formaldeIllinois) as previously described (Mabjeesh et al., 2002) .
hyde, 0.05% glutaraldehyde, 0.5% Triton X-100 for 10 min at room temperature. Coverslips were blocked in 10% goat serum/PBS for 10 min and processed for double-labeling immunofluorescence with rat anti-␣-tubulin, Pulse chase assay PC-3 cells grown in 6-well plates were labeled with 35 S-methionine as demouse anti HIF-1␣, and mouse anti-HIF-1␤ antibodies. The secondary antibodies were Alexa Fluor 488 goat anti-mouse antibody and Alexa Fluor 568 scribed above. The radioactive medium was then removed and cells were recultured in complete medium with 0.1% DMSO or 100 M 2ME2 for goat anti-rat antibody antibodies. Coverslips were then mounted onto glass
